Successful process development enables a seamless supply from research quantities to commercial product delivery. Starting with the small quantities of our traditional solid phase synthesis, we are able to scale up to 20 kg.

Our team works diligently to prove the equivalency in quality between batches and to design a manufacturing process that supports pre-clinical to commercial launch.

Our specialized facilities offer the manufacturing flexibility to scale up your oligonucleotide product from non-clinical studies to cGMP production for clinical trials and commercial needs, including quality evaluations and long-term stability studies.